Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
² Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA.
³ Department of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA.
⁴ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA. drilona@mskcc.org.
⁵ Weill Cornell Medical College, New York, NY, USA. drilona@mskcc.org.
⁶ Department of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA. davarem@ohsu.edu.
⁷ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA. davarem@ohsu.edu.

^# Contributed equally.

Published Erratum

Rajat Thawani et al. NPJ Precis Oncol. 2024.

. 2024 Aug 28;8(1):184.

doi: 10.1038/s41698-024-00676-w.

¹ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
² Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA.
³ Department of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA.
⁴ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA. drilona@mskcc.org.
⁵ Weill Cornell Medical College, New York, NY, USA. drilona@mskcc.org.
⁶ Department of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA. davarem@ohsu.edu.
⁷ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA. davarem@ohsu.edu.

^# Contributed equally.

No abstract available

Erratum for

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA. Thawani R, et al. NPJ Precis Oncol. 2024 Aug 8;8(1):175. doi: 10.1038/s41698-024-00663-1. NPJ Precis Oncol. 2024. PMID: 39117775 Free PMC article.